CASI Pharma's CID-103 Faces FDA Clinical Hold

TL;DR

FDA slaps clinical hold on CASI's kidney transplant drug CID-103 due to rejection concerns.

AI Summary

On December 26, 2024, CASI Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its investigational drug CID-103. This hold is related to the drug's potential for antibody-mediated rejection (AMR) in kidney transplant patients. CASI Pharmaceuticals is working with the FDA to address the concerns and determine the next steps for the drug's development.

Why It Matters

This clinical hold significantly impacts the development timeline and potential market entry for CID-103, a drug intended for a critical unmet need in kidney transplant patients.

Risk Assessment

Risk Level: high — A clinical hold by the FDA is a significant setback that can delay or halt drug development, posing a substantial risk to the company's pipeline and future revenue.

Key Players & Entities

• CASI Pharmaceuticals, Inc. (company) — Registrant
• CID-103 (drug) — Investigational drug subject to clinical hold
• U.S. Food and Drug Administration (FDA) (company) — Regulatory body that issued the clinical hold
• December 26, 2024 (date) — Date of announcement
• Antibody Mediated Rejection (AMR) (medical_condition) — Reason for clinical hold
• Kidney Transplant (medical_procedure) — Target patient population

FAQ

Filing Documents

• tm2431957d1_6k.htm (6-K) — 12KB
• 0001104659-24-131547.txt ( ) — 13KB

Forward-Looking Statements

Forward-Looking Statements This 6-K contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking contained herein. INCORPORATION BY REFERENCE The information included in this Report on Form 6-K is hereby incorporated by reference into the Company's Registration Statement[s] on Form F-3 ( File No. 333-283998 [and File No. 333-281621 ]) (including any prospectuses forming a part of such registration statement[s]) and to be a part thereof from the date on which this Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ Wei-Wu He Name: Wei-Wu He Title: Chairman & CEO Date: December 26, 2024

View Full Filing

View this 6-K filing on SEC EDGAR